{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:01:59Z","timestamp":1778198519799,"version":"3.51.4"},"reference-count":229,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.ecl.2004.11.006","type":"journal-article","created":{"date-parts":[[2005,4,18]],"date-time":"2005-04-18T10:53:30Z","timestamp":1113821610000},"page":"155-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Novel Pharmacologic Agents for Type 2 Diabetes"],"prefix":"10.1016","volume":"34","author":[{"given":"Gabriel I.","family":"Uwaifo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00126839-199902020-00001","article-title":"Recent developments and emerging therapies for type 2 diabetes mellitus","volume":"2","author":"Evans","year":"1999","journal-title":"Drugs R D"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1568005310202010063","article-title":"Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus","volume":"2","author":"Baron","year":"2002","journal-title":"Curr Drug Targets Immune Endocr Metabol Disord"},{"key":"10.1016\/j.ecl.2004.11.006_bib3","unstructured":"Kinalski M, Sledziewski A, Telejko B, et al. Postpartum evaluation of amylin levels in gestational diabetes mellitus. American Diabetes Association, 62nd Scientific Sessions, June 2002. San Francisco, California."},{"issue":"6","key":"10.1016\/j.ecl.2004.11.006_bib4","first-page":"524","article-title":"Roles of amylin in diabetes and in regulation of nutrient load","volume":"14","author":"Young","year":"1998","journal-title":"Nutrition"},{"issue":"5","key":"10.1016\/j.ecl.2004.11.006_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2337\/diacare.21.5.810","article-title":"Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM","volume":"21","author":"Rachman","year":"1998","journal-title":"Diabetes Care"},{"issue":"12 Suppl 1","key":"10.1016\/j.ecl.2004.11.006_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1100\/tsw.2001.449","article-title":"Amylin as a neuroendocrine hormone","volume":"1","author":"Young","year":"2001","journal-title":"Scientific World Journal"},{"issue":"1 Pt 1","key":"10.1016\/j.ecl.2004.11.006_bib7","first-page":"E19","article-title":"Islet amyloid polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat pancreatic islets","volume":"276","author":"Wang","year":"1999","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0026-0495(97)90170-0","article-title":"Dose-response for glucagonostatic effect of amylin in rats","volume":"46","author":"Gedulin","year":"1997","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib9","doi-asserted-by":"crossref","first-page":"E443","DOI":"10.1152\/ajpendo.2001.280.3.E443","article-title":"Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas","volume":"280","author":"Silvestre","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib10","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s001250050646","article-title":"Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM","volume":"40","author":"Kong","year":"1997","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.ecl.2004.11.006_bib11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s001250050949","article-title":"The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM","volume":"41","author":"Kong","year":"1998","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1210\/endo.141.2.7378","article-title":"Amylin: a novel action in the brain to reduce body weight","volume":"141","author":"Rushing","year":"2000","journal-title":"Endocrinology"},{"issue":"2\u20133","key":"10.1016\/j.ecl.2004.11.006_bib13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0167-0115(95)00009-Z","article-title":"In vivo central actions of rat amylin","volume":"56","author":"Bouali","year":"1995","journal-title":"Regul Pept"},{"issue":"6","key":"10.1016\/j.ecl.2004.11.006_bib14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2337\/diacare.21.6.987","article-title":"Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group","volume":"21","author":"Thompson","year":"1998","journal-title":"Diabetes Care"},{"issue":"7\u20138","key":"10.1016\/j.ecl.2004.11.006_bib15","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1345\/aph.1C387","article-title":"Pramlintide for the treatment of diabetes mellitus","volume":"37","author":"Kleppinger","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2982.2002.00311.x","article-title":"Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus","volume":"14","author":"Vella","year":"2002","journal-title":"Neurogastroenterol Motil"},{"issue":"14","key":"10.1016\/j.ecl.2004.11.006_bib17","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr Pharm Des"},{"issue":"11","key":"10.1016\/j.ecl.2004.11.006_bib18","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.2337\/diacare.26.11.3074","article-title":"Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study","volume":"26","author":"Weyer","year":"2003","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2004.11.006_bib19","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1517\/13543784.10.9.1641","article-title":"Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus","volume":"10","author":"Nyholm","year":"2001","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib20","first-page":"1083","article-title":"Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus","volume":"81","author":"Nyholm","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ecl.2004.11.006_bib21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0026-0495(99)90232-9","article-title":"The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus","volume":"48","author":"Nyholm","year":"1999","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.ecl.2004.11.006_bib22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1055\/s-2002-34790","article-title":"The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus","volume":"34","author":"Fineman","year":"2002","journal-title":"Horm Metab Res"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2982.2002.00311.x","article-title":"Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and type 2 diabetes mellitus","volume":"14","author":"Vella","year":"2002","journal-title":"Neurogastroenterol Motil"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib24","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI111519","article-title":"Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy","volume":"74","author":"Pehling","year":"1984","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00400639","article-title":"Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM","volume":"38","author":"Dinneen","year":"1995","journal-title":"Diabetologia"},{"key":"10.1016\/j.ecl.2004.11.006_bib26","unstructured":"Gedulin BR, Smith P, Gedulin G, et al. Amylin potently inhibits Ghrelin secretion in rats. American Diabetes Association, 64th Scientific Sessions, 2004. Orlando, Florida."},{"issue":"6","key":"10.1016\/j.ecl.2004.11.006_bib27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1463-1326.2003.00295.x","article-title":"Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets","volume":"5","author":"Hollander","year":"2003","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib28","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ecl.2004.11.006_bib29","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.metabol.2003.06.003","article-title":"Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: A pooled post hoc analysis","volume":"52","author":"Maggs","year":"2003","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib31","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.26.1.1","article-title":"Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps","volume":"26","author":"Levetan","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2004.11.006_bib33","unstructured":"Heptulla RA, Rodriguez LM, Haymond MW. Post-prandial (PP) glucose homeostasis inpediatric T1 D: Role of Pramlintide as adjunctive therapy. American Diabetes Association, 64th Scientific Sessions, 2004. Orlando, Florida."},{"key":"10.1016\/j.ecl.2004.11.006_bib34","doi-asserted-by":"crossref","unstructured":"Weyer C, Wang Y, Schnabel C, et al. Pramlintide pharmacokinetics in type 1 and type 2 diabetes; effects of injection site, needle length and body size. American Diabetes Association, 64th Scientific Sessions, 2004. Orlando, Florida.","DOI":"10.1016\/S1530-891X(20)46398-0"},{"key":"10.1016\/j.ecl.2004.11.006_bib35","unstructured":"Want LL, Ratner R, Uwaifo GI. Safety and tolerability of long term pramlintide therapy. American Diabetes Association, 64th Scientific Sessions, 2004. Orlando, Florida."},{"key":"10.1016\/j.ecl.2004.11.006_bib36","unstructured":"Chapman I, Parker B, Doran S, et al. Effect of pramlintide on Ad-libitum food intake in obese subjects and subjects with type 2 diabetes: A randomized, double blind, placebo controlled, cross-over study. American Diabetes Association, 64th Scientific Sessions, 2004. Orlando, Florida."},{"key":"10.1016\/j.ecl.2004.11.006_bib37","doi-asserted-by":"crossref","unstructured":"Marrero D, Kruger D, Burrell T, et al. Patients with type 1-diabetes: perceptions associated with pramlintide as an adjunctive treatment to insulin. American Diabetes Association, 64th Scientific Sessions, 2004. Orlando, Florida.","DOI":"10.1016\/S1530-891X(20)46396-7"},{"key":"10.1016\/j.ecl.2004.11.006_bib38","unstructured":"Levetan C, Want LL, Weyer C, et al. Reduced glucose fluctuations following 4 weeks of pramlintide treatment in patients with type 1 diabetes intensively treated with insulin pumps. American Diabetes Association, 2002. San Francisco, California."},{"key":"10.1016\/j.ecl.2004.11.006_bib39","doi-asserted-by":"crossref","unstructured":"Want LL, Levetan C, Weyer C, et al. Reduced postprandial glucose, glucagon and triglyceride excursions following 4 weeks of pramlintide treatment in patients with type 1 diabetes treated intensively with insulin pumps. American Diabetes Association, 62nd Scientific Sessions, 2002. San Francisco, California.","DOI":"10.2337\/diacare.26.1.1"},{"issue":"7","key":"10.1016\/j.ecl.2004.11.006_bib40","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1358\/dnp.2003.16.7.829353","article-title":"Incretins and their analogues as new antidiabetic drugs","volume":"16","author":"Nauck","year":"2003","journal-title":"Drug News Perspect"},{"issue":"11","key":"10.1016\/j.ecl.2004.11.006_bib41","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diabetes.47.11.1663","article-title":"Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes","volume":"47","author":"Holst","year":"1998","journal-title":"Diabetes"},{"issue":"22","key":"10.1016\/j.ecl.2004.11.006_bib42","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2174\/0929867033456648","article-title":"Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus","volume":"10","author":"Holz","year":"2003","journal-title":"Curr Med Chem"},{"issue":"10","key":"10.1016\/j.ecl.2004.11.006_bib43","first-page":"690","article-title":"Glucagon-like peptide-1 structure, function and potential use for NIDDM","volume":"33","author":"Gefel","year":"1997","journal-title":"Isr J Med Sci"},{"key":"10.1016\/j.ecl.2004.11.006_bib44","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1210\/rp.56.1.377","article-title":"Glucagon-like peptide-1","volume":"56","author":"Doyle","year":"2001","journal-title":"Recent Prog Horm Res"},{"issue":"9","key":"10.1016\/j.ecl.2004.11.006_bib45","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2337\/diab.42.9.1219","article-title":"Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM","volume":"42","author":"Thorens","year":"1993","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.ecl.2004.11.006_bib46","first-page":"311","article-title":"Glucagon-like peptide-1 and control of insulin secretion","volume":"21","author":"Thorens","year":"1995","journal-title":"Diabete Metab"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib47","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients","volume":"50","author":"Vilsboll","year":"2001","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.ecl.2004.11.006_bib48","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2004.11.006_bib49","doi-asserted-by":"crossref","unstructured":"Vilsboll T, Krarup T, Holst JJ. Similar elimination rates of GLP-1 in obese type 2 diabetes patients and matched healthy subjects. American Diabetes Association, 62nd Scientific Sessions, 2002. San Francisco, California.","DOI":"10.1210\/jc.2002-021053"},{"issue":"12","key":"10.1016\/j.ecl.2004.11.006_bib50","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1210\/endo.141.12.7806","article-title":"Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats","volume":"141","author":"Perfetti","year":"2000","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.ecl.2004.11.006_bib51","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1530\/eje.0.1430717","article-title":"Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function","volume":"143","author":"Perfetti","year":"2000","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib52","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/diabetes.52.2.365","article-title":"Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy","volume":"52","author":"De Leon","year":"2003","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib53","first-page":"A31","article-title":"The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rat bet a cells","volume":"50","author":"Bregenholt","year":"2001","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2004.11.006_bib54","first-page":"A19","article-title":"The GLP-1 analogue, NN2211, inhibits free fatty acid induced apoptosis in primary rat beta cells","volume":"44","author":"Bregenholt","year":"2001","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib55","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1074\/jbc.M209423200","article-title":"Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.ecl.2004.11.006_bib56","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/diabetes.50.7.1562","article-title":"Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age","volume":"50","author":"Tourrel","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.ecl.2004.11.006_bib57","unstructured":"Benthem L, Wei L, Langer KZ, et al. The long acting GLP-1 derivative NN2211 improves glucose tolerance and normalizes body weight in diet induced obese rats. American Diabetes Association, 62nd Scientific Sessions, 2002. San Francisco, California."},{"key":"10.1016\/j.ecl.2004.11.006_bib58","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/BF01540341","article-title":"GLP-1 (glucagon-like peptide 1) and truncated GLP-1 fragements of human proglucagon, inhibit gatsric acid sceretion in humans","volume":"34","author":"Schjoldager","year":"1989","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.ecl.2004.11.006_bib59","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2337\/diab.43.4.535","article-title":"Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans","volume":"43","author":"Orskov","year":"1994","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib60","first-page":"327","article-title":"Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients","volume":"81","author":"Willms","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ecl.2004.11.006_bib61","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib62","first-page":"84","article-title":"Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men","volume":"109","author":"Schirra","year":"1997","journal-title":"Proc Assoc Am Physicians"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib63","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF00581038","article-title":"Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects","volume":"32","author":"Qualmann","year":"1995","journal-title":"Acta Diabetol"},{"issue":"9","key":"10.1016\/j.ecl.2004.11.006_bib64","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3109\/00365529509101597","article-title":"Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)","volume":"30","author":"Qualmann","year":"1995","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib65","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0029-1211750","article-title":"Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes","volume":"105","author":"Nauck","year":"1997","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"9","key":"10.1016\/j.ecl.2004.11.006_bib66","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-2007-979067","article-title":"Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus","volume":"29","author":"Nauck","year":"1997","journal-title":"Horm Metab Res"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib67","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/diabetes.51.2.424","article-title":"Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes","volume":"51","author":"Juhl","year":"2002","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.ecl.2004.11.006_bib68","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.2337\/diacare.25.8.1398","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects","volume":"25","author":"Elbrond","year":"2002","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","article-title":"The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men","volume":"45","author":"Agerso","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.ecl.2004.11.006_bib70","unstructured":"Matthews D, Madsbad S, Schmitz O, et al. The long acting GLP-1 derivative, NN2211, a new agent for the treatment of type 2 diabetes. American Diabetes Association, 62nd Scientific Sessions, 2002. San Francisco, California."},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib71","first-page":"A83","article-title":"Liraglutide significantly improves glycemic control and reduces body weight compared with glimeperide as add-on to metformin in type 2 diabetes","volume":"53","author":"Nauck","year":"2004","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.ecl.2004.11.006_bib72","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.2337\/diab.42.11.1678","article-title":"Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor","volume":"42","author":"Thorens","year":"1993","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib73","first-page":"A104","article-title":"Subcutaneous injection of AC 2993 (synthetic exendin-40) lowered fasting glucose concentrations through suppression of glucagon and dose dependent insulinotropism in patients with type 2 diabetes","volume":"51","author":"Kim","year":"2002","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib74","first-page":"A85","article-title":"AC 2993 (synthetic exendin-4) added to exisiting metformin (MET) and\/or sulfonylurea (SFU) treatment improved glycemic control in patients with type 2 diabetes (DM2) during 28 days of treatment","volume":"51","author":"Fineman","year":"2002","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.ecl.2004.11.006_bib75","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/diacare.26.8.2370","article-title":"Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and\/or sulfonylurea treatment in patients with type 2 diabetes","volume":"26","author":"Fineman","year":"2003","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib76","first-page":"S265","article-title":"The Amigo trials; Exenatide phase 3 trials; (Abstract)","volume":"29","author":"Taylor","year":"2003","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ecl.2004.11.006_bib77","unstructured":"Taylor K, et al. The Amigo trials; Phase 3 trials of Exenatide-oral presentation. American Diabetes Association Scientific Sessions, 2004. Orlando, Florida."},{"issue":"7","key":"10.1016\/j.ecl.2004.11.006_bib78","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2002-021545","article-title":"Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes","volume":"88","author":"Kolterman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2004.11.006_bib79","unstructured":"Hiles R, Carpenter T, Serota D, et al. Exenatide does not cause pancreatic islet cell proliferative leions in rats and mice following 2 year exposure. American Diabetic Association, 64th Scientific Sessions, 2004. Orlando, Florida."},{"issue":"11","key":"10.1016\/j.ecl.2004.11.006_bib80","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib81","first-page":"A93","article-title":"The long acting GLP-1 agonist CJC 1131 exhibits high potency and extended pharmacokinetics in vivo","volume":"51","author":"Bridon","year":"2002","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib82","first-page":"A84","article-title":"CJC-1131, the novel long acting GLP-1 analogue, delays gastric emptying and demonstrates safety and tolerability in preclinical testing","volume":"51","author":"Lawrence","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ecl.2004.11.006_bib83","unstructured":"Wen SY, Chatenoud L, Lawrence B, et al. Lack of immunogenicity of CJC-1131, a long acting GLP-1 analog for the treatment of type 2 diabetes. American Diabetes Association, 64th Scientific session, 2004. Orlando, Florida."},{"key":"10.1016\/j.ecl.2004.11.006_bib84","unstructured":"Kim J, Baggio L, Drucker DJ. The GLP-1-DAC analogue CJC-1131 upregulates insulin gene expression and exerts a memory effect on glycemic control in db\/db mice. American Diabetes Association, 62nd Scientific Sessions, 2002. San Francisco, CA."},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib85","first-page":"A127","article-title":"CJC-1131, a long acting GLP-1 analog safely normalizes post-prandial glucose excursion and fasting glycemia in type 2 diabetes mellitus","volume":"53","author":"Guivarc'h","year":"2004","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib86","first-page":"A84","article-title":"Daily administration of LY307161 (GLP-1 analog) normalizes blood glucose on type 2 diabetes","volume":"51","author":"Kaptiza","year":"2002","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib87","first-page":"A135","article-title":"LY 307161 SR, a sustained release formulation of GLP-1 analog, is suitable for once daily administration in patients with type 2 diabetes","volume":"51","author":"Trautmann","year":"2002","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2004.11.006_bib88","first-page":"A145","article-title":"LY307161: A fully active DPP-IV resistant analogue of GLP-1","volume":"43","author":"Hoffman","year":"2000","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.ecl.2004.11.006_bib89","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2337\/diacare.19.8.843","article-title":"Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet","volume":"19","author":"Gutniak","year":"1996","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.ecl.2004.11.006_bib90","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.2337\/diacare.20.12.1874","article-title":"GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions","volume":"20","author":"Gutniak","year":"1997","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ecl.2004.11.006_bib91","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diacare.26.10.2929","article-title":"Enhancing incretin action for the treatment of type 2 diabetes","volume":"26","author":"Drucker","year":"2003","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib92","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1517\/13543784.12.1.87","article-title":"Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes","volume":"12","author":"Drucker","year":"2003","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ecl.2004.11.006_bib93","unstructured":"Ryskjaer J, Carr RD, Krarup T, et al. Increased plasma DPP-IV activity in type 2 diabetic patients in the fasting state. American Diabetes Association, 64th Scientific Sessions, 2002. Orlando, Florida."},{"key":"10.1016\/j.ecl.2004.11.006_bib94","unstructured":"Conarello SL, Li Z, Shelton B, et al. Dipeptidyl peptidase knockout mice are protected against high fat diet-induced obesity and insulin resistance. American Diabetes Association, 62nd Scientific Sessions, 2002. San Francisco, California."},{"key":"10.1016\/j.ecl.2004.11.006_bib95","unstructured":"Tadayyon M, Thomas L, Besenfelder U, et al. Identification of long acting DPP-IV inhibitors and their effect on diabetes prevention and insulin sensitivity in db\/db mice. American Diabetes Association, 64th Scientific Sessions, 2004. Orlando, Florida."},{"issue":"7","key":"10.1016\/j.ecl.2004.11.006_bib96","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2337\/diabetes.50.7.1588","article-title":"Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs","volume":"50","author":"Deacon","year":"2001","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.ecl.2004.11.006_bib97","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2337\/diabetes.47.5.764","article-title":"Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig","volume":"47","author":"Deacon","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.ecl.2004.11.006_bib98","unstructured":"Knudsen LB, Voss PV, Rolin B, et al. Liraglutide, along acting GLP-1 derivative, reduces body weight and food intake in obese candy fed rats while the DPP-IV inhibitor LAF237 does not. American Diabetes Association, 64th Scientific Sessions, 2004. Orlando, Florida."},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2004.11.006_bib99","first-page":"A39","article-title":"Treatment with DPP -IV inhibitor, NVP-DPP-728, increases prandial intact GLP-1 levels and reduces glucose exposure in humans","volume":"49","author":"Rothenberg","year":"2000","journal-title":"Diabetes"},{"issue":"1\u20132","key":"10.1016\/j.ecl.2004.11.006_bib100","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0014-2999(00)00600-2","article-title":"Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice","volume":"404","author":"Ahren","year":"2000","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.ecl.2004.11.006_bib101","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2337\/diacare.25.5.869","article-title":"Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes","volume":"25","author":"Ahren","year":"2002","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib102","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1254\/jjp.88.451","article-title":"Dipeptidyl peptidase IV inhibitor NVP-DPP728 ameliorates early insulin response and glucose tolerance in aged rats but not in aged Fischer 344 rats lacking its enzyme activity","volume":"88","author":"Mitani","year":"2002","journal-title":"Jpn J Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib103","first-page":"A82","article-title":"The DPP-IV Inhibitor MK-0431 enhances active GLP-1 and reduces glucose following OGTT in tyoe 2 diabetics","volume":"53","author":"Herman","year":"2004","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.ecl.2004.11.006_bib104","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1210\/jc.2003-031907","article-title":"Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes","volume":"89","author":"Ahren","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib105","first-page":"A83","article-title":"The DPP-IV Inhibitor, LAF237, improves glycemic control in patients with type 2 diabetes (T2DM) inadequately treated with metformin","volume":"53","author":"Ahren","year":"2004","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.ecl.2004.11.006_bib106","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve and 52 week efficacy of the dipeptidyl IV inhibitor LAF237 in metformin treated patients who have type 2 diabetes","volume":"27","author":"Ahren","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib107","first-page":"A83","article-title":"Twelve week monotherapy with the DPP-4 Inhibitor, LAF237 improves glycemic control in patients with type 2 diabetes (T2DM)","volume":"53","author":"Pratley","year":"2004","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0167-0115(99)00089-0","article-title":"Dipeptidyl-peptidase IV (CD26)\u2014role in the inactivation of regulatory peptides","volume":"85","author":"Mentlein","year":"1999","journal-title":"Regul Pept"},{"issue":"5","key":"10.1016\/j.ecl.2004.11.006_bib109","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11892-003-0079-9","article-title":"Gut peptides and type 2 diabetes mellitus treatment","volume":"3","author":"Ahren","year":"2003","journal-title":"Curr Diab Rep"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib110","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/0929867306666220208213543","article-title":"The unique properties of dipeptidyl-peptidase IV (DPP IV \/ CD26) and the therapeutic potential of DPP IV inhibitors","volume":"6","author":"Augustyns","year":"1999","journal-title":"Curr Med Chem"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib111","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11892-001-0023-9","article-title":"New pharmacologic agents for diabetes","volume":"1","author":"Bailey","year":"2001","journal-title":"Curr Diab Rep"},{"issue":"16","key":"10.1016\/j.ecl.2004.11.006_bib112","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/S0960-894X(03)00505-5","article-title":"5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha\/gamma agonists as antidiabetic agents","volume":"13","author":"Desai","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"issue":"20","key":"10.1016\/j.ecl.2004.11.006_bib113","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1016\/S0960-894X(03)00785-6","article-title":"Aryloxazolidinediones: identification of potent orally active PPAR dual alpha\/gamma agonists","volume":"13","author":"Desai","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"10.1016\/j.ecl.2004.11.006_bib114","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0960-894X(02)01029-6","article-title":"Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists","volume":"13","author":"Adams","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"issue":"19","key":"10.1016\/j.ecl.2004.11.006_bib115","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1016\/S0960-894X(03)00702-9","article-title":"O-arylmandelic acids as highly selective human PPAR alpha\/gamma agonists","volume":"13","author":"Adams","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib116","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1161\/01.HYP.0000084370.74777.B6","article-title":"Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension","volume":"42","author":"Schiffrin","year":"2003","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib117","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.HYP.0000083511.91817.B1","article-title":"Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension","volume":"42","author":"Iglarz","year":"2003","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib118","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/01.ATV.0000047447.67827.CD","article-title":"Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension","volume":"23","author":"Iglarz","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.ecl.2004.11.006_bib119","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1096\/fj.01-0793com","article-title":"Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size","volume":"16","author":"Wayman","year":"2002","journal-title":"FASEB J"},{"issue":"5","key":"10.1016\/j.ecl.2004.11.006_bib120","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1152\/ajpendo.00149.2002","article-title":"Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db\/db mice","volume":"284","author":"Yajima","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2004.11.006_bib121","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1194\/jlr.M200127-JLR200","article-title":"AZ 242, a novel PPARalpha\/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob\/ob mice and obese Zucker rats","volume":"43","author":"Ljung","year":"2002","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib122","doi-asserted-by":"crossref","first-page":"E531","DOI":"10.1152\/ajpendo.00299.2002","article-title":"PPARalpha\/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly","volume":"284","author":"Ye","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib123","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0021-9150(02)00203-4","article-title":"Peroxisome proliferator-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression","volume":"165","author":"Li","year":"2002","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib124","first-page":"449","article-title":"Insulin detemir. Novo Nordisk","volume":"4","author":"Barlocco","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib125","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/diabetes.51.3.762","article-title":"Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake","volume":"51","author":"Dea","year":"2002","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib126","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2337\/diacare.26.3.590","article-title":"Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart","volume":"26","author":"Vague","year":"2003","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib127","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2337\/diacare.24.2.296","article-title":"Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy","volume":"24","author":"Hermansen","year":"2001","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib128","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1055\/s-2000-5887","article-title":"Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans","volume":"108","author":"Brunner","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"10","key":"10.1016\/j.ecl.2004.11.006_bib129","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s001250051301","article-title":"Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin","volume":"42","author":"Hamilton-Wessler","year":"1999","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.ecl.2004.11.006_bib130","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1021\/bi9625105","article-title":"Crystal structure of a prolonged-acting insulin with albumin-binding properties","volume":"36","author":"Whittingham","year":"1997","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib131","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1046\/j.1464-5491.1999.00081.x","article-title":"Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304","volume":"16","author":"Heinemann","year":"1999","journal-title":"Diabet Med"},{"issue":"5","key":"10.1016\/j.ecl.2004.11.006_bib132","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2337\/diacare.27.5.1081","article-title":"Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial","volume":"27","author":"Home","year":"2004","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib133","first-page":"A144","article-title":"Benefits of Insulin Detemir over NPH insulin in children and adolescents with type 1 diabetes: Lower and more predictable fastong plasma glucose and lower risk of nocturnal hypoglycemia","volume":"53","author":"Robertson","year":"2004","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib134","first-page":"A125","article-title":"Treatment with insulin Detemir provides improved glycemic control and less weight gain compared to NPH insulin in people with diabetes","volume":"53","author":"Garber","year":"2004","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib135","first-page":"A145","article-title":"Feasibility of improved glycemic control with insulin Detemir and Insulin Glargine in combination with oral agents in insulin naive patients with type 2 diabetes","volume":"53","author":"Rosenstock","year":"2004","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.ecl.2004.11.006_bib136","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1021\/js9701768","article-title":"Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue","volume":"86","author":"Kurtzhals","year":"1997","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.ecl.2004.11.006_bib137","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2337\/diabetes.49.6.999","article-title":"Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use","volume":"49","author":"Kurtzhals","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.ecl.2004.11.006_bib138","unstructured":"Su M, Testa MA, Turner RR, et al. The relationship between regimen burden and psychological well being in persons with type 1 diabetes: inhaled vs injectable insulin [abstract]. American Diabetes Association, 62nd Scientific session, 2002. San Francisco, California."},{"issue":"6","key":"10.1016\/j.ecl.2004.11.006_bib139","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.2337\/diacare.27.6.1318","article-title":"Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes","volume":"27","author":"Rosenstock","year":"2004","journal-title":"Diabetes Care"},{"issue":"14","key":"10.1016\/j.ecl.2004.11.006_bib140","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/1381612013397384","article-title":"Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery","volume":"7","author":"Heinemann","year":"2001","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10.1016\/j.ecl.2004.11.006_bib141","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1378\/chest.114.6.1734","article-title":"The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes","volume":"114","author":"Laube","year":"1998","journal-title":"Chest"},{"issue":"3 Suppl","key":"10.1016\/j.ecl.2004.11.006_bib142","doi-asserted-by":"crossref","first-page":"99S","DOI":"10.1378\/chest.120.3_suppl.99S","article-title":"Treating diabetes with aerosolized insulin","volume":"120","author":"Laube","year":"2001","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2004.11.006_bib143","first-page":"A7","article-title":"Results of a dose response study with a new pulmonary insulin formulation and inhaler","volume":"49","author":"Rave","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.ecl.2004.11.006_bib144","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/152091502320798204","article-title":"Technosphere insulin\u2014a new approach for effective delivery of human insulin via the pulmonary route","volume":"4","author":"Pfutzner","year":"2002","journal-title":"Diabetes Technol Ther"},{"issue":"5320","key":"10.1016\/j.ecl.2004.11.006_bib145","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1126\/science.276.5320.1868","article-title":"Large porous particles for pulmonary drug delivery","volume":"276","author":"Edwards","year":"1997","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.ecl.2004.11.006_bib146","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2337\/diacare.23.9.1343","article-title":"Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer","volume":"23","author":"Heinemann","year":"2000","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ecl.2004.11.006_bib147","first-page":"417","article-title":"Alternative delivery routes: inhaled insulin","volume":"15","author":"Heinemann","year":"2002","journal-title":"Diabetes Nutr Metab"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib148","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/(SICI)1096-9136(199701)14:1<63::AID-DIA298>3.0.CO;2-F","article-title":"Time-action profile of inhaled insulin","volume":"14","author":"Heinemann","year":"1997","journal-title":"Diabet Med"},{"key":"10.1016\/j.ecl.2004.11.006_bib149","unstructured":"Rosenstock J. Mealtime rapid acting inhaled insulin (Exubera) improves glycemic control in patients with type 2 diabetes failing combination oral agents: a 3 month, randomized, comparative trial. American Diabetes Association, 62nd Scientific Sessions, 2002. San Francisco, California."},{"key":"10.1016\/j.ecl.2004.11.006_bib150","unstructured":"Heise T, Tusek C, Stephan J, et al. Insulin antibodies with inhaled insulin (Exubera(r)); No evidence for impact on postprandial glucose control. American Diabetes Association, 64th Scientific session, 2004. Orlando, Florida."},{"issue":"12","key":"10.1016\/j.ecl.2004.11.006_bib151","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.2337\/diacare.23.12.1799","article-title":"Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes","volume":"23","author":"Cappelleri","year":"2000","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib152","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0149-2918(02)85131-1","article-title":"Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen","volume":"24","author":"Cappelleri","year":"2002","journal-title":"Clin Ther"},{"issue":"19","key":"10.1016\/j.ecl.2004.11.006_bib153","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/archinte.163.19.2277","article-title":"Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial","volume":"163","author":"Weiss","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ecl.2004.11.006_bib154","unstructured":"Sha S, Becker RHA, Willavise SA, et al. The effect of smoking cessation on the absorption of inhaled insulin (Exubera(r)). American Diabetes Association, 62nd Scientific Sessions, 2002. San Francisco, California."},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib155","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2337\/diacare.26.3.677","article-title":"The impact of smoking on inhaled insulin","volume":"26","author":"Himmelmann","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2004.11.006_bib156","unstructured":"Barnett AH. Efficacy and one year pulmonary safety of inhaled insulin (Exubera(r)) as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled on oral agent monotherapy. American Diabetes Association, 64th Scientific Sessions, 2004. Orlando, Florida."},{"key":"10.1016\/j.ecl.2004.11.006_bib157","unstructured":"Skyler JS. Sustained long term efficacy and safety of inhaled insulin during 4 years of continuous therapy. American Diabetes Association, 64th Scientific Sessions, 2004. Orlando, Florida."},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib158","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2337\/diacare.27.1.162","article-title":"Intensive Therapy With Inhaled Insulin via the AERx Insulin Diabetes Management System: A 12-week proof-of-concept trial in patients with type 2 diabetes","volume":"27","author":"Hermansen","year":"2004","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ecl.2004.11.006_bib159","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/0091270003258657","article-title":"Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison","volume":"43","author":"Henry","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ecl.2004.11.006_bib160","doi-asserted-by":"crossref","unstructured":"Henry R, Mudaliar S, Chu N, et al. Pharmacokinetics and pharmacodynamics of pulmonary insulin in young and elderly type 2 diabetic patients using the AERx(r) Insulin diabetes management system. American Diabetes Association, 62nd Scientific Sessions, 2002. San Francisco, California.","DOI":"10.1177\/0091270003258657"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib161","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2337\/diacare.26.3.764","article-title":"Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects","volume":"26","author":"Henry","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ecl.2004.11.006_bib162","unstructured":"McElduff A, Clauson P, Uy C, et al. Pulmonary absorption profiles of insulin during and after an upper respiratory tract infection in healthy volunteers using the AERx(r) insulin diabetes management system. An open labelled cross-over study in healthy volunteers. American Diabetes Association, 62nd Scientific Sessions, 2002. San Francisco, California."},{"key":"10.1016\/j.ecl.2004.11.006_bib163","unstructured":"Hermansen K, Ronnemaa T, Petersen AH, et al. Intensive treatment with pulmonary insulin using the AERx(r) Insulin diabetes management system\u2014a proof of concept trial in type 2 diabetic patients. American Diabetes Association, 62nd Scientific Sessions, 2002. San Francisco, California."},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib164","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2002-19989","article-title":"Technosphere\/Insulin\u2014proof of concept study with a new insulin formulation for pulmonary delivery","volume":"110","author":"Steiner","year":"2002","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.ecl.2004.11.006_bib165","unstructured":"Cheatham WW, Anders BH, Forst T, et al. A novel pulmonary insulin formulation replicates first phase insulin release and reduces s-proinsulin. American Diabetes Association, 64th Scientific Sessions, 2004. Orlando, Florida."},{"key":"10.1016\/j.ecl.2004.11.006_bib166","unstructured":"Kim D, Mudaliar S, Plodkowski R, et al. Dose-response relationships of inhaled and subcutaneous insulin in type 2 diabetic patients. American Diabetes Association, 62nd Scientific Sessions, 2002. San Francisico, California."},{"issue":"10","key":"10.1016\/j.ecl.2004.11.006_bib167","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.2337\/diacare.26.10.2842","article-title":"Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes","volume":"26","author":"Kim","year":"2003","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ecl.2004.11.006_bib168","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1089\/152091502320798312","article-title":"Variability of insulin absorption and insulin action","volume":"4","author":"Heinemann","year":"2002","journal-title":"Diabetes Technol Ther"},{"issue":"Suppl","key":"10.1016\/j.ecl.2004.11.006_bib169","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/BF02718194","article-title":"Aerosols for systemic treatment","volume":"168","author":"Kohler","year":"1990","journal-title":"Lung"},{"issue":"8678\u20139","key":"10.1016\/j.ecl.2004.11.006_bib170","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(89)92954-1","article-title":"Oral delivery of insulin","volume":"2","author":"Cho","year":"1989","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib171","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1440-1681.1982.tb00819.x","article-title":"Infrequent response by diabetic rats to insulin-liposomes","volume":"9","author":"Shenfield","year":"1982","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"4768","key":"10.1016\/j.ecl.2004.11.006_bib172","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1126\/science.3526553","article-title":"A new approach to the oral administration of insulin and other peptide drugs","volume":"233","author":"Saffran","year":"1986","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.ecl.2004.11.006_bib173","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1016\/0024-3205(81)90176-4","article-title":"Oral ingestion of insulin liposomes: effects of the administration route","volume":"28","author":"Weingarten","year":"1981","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib174","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0306-3623(91)90440-H","article-title":"Insulin and C-peptide levels following oral administration of insulin in intestinal-enzyme protected capsules","volume":"22","author":"Gwinup","year":"1991","journal-title":"Gen Pharmacol"},{"issue":"13","key":"10.1016\/j.ecl.2004.11.006_bib175","first-page":"448","article-title":"[Oral administration of insulin by means of liposomes in animal experiments (author's translation)]","volume":"91","author":"Tragl","year":"1979","journal-title":"Wien Klin Wochenschr"},{"issue":"9","key":"10.1016\/j.ecl.2004.11.006_bib176","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/js980337n","article-title":"Oral delivery of insulin using pH-responsive complexation gels","volume":"88","author":"Lowman","year":"1999","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib177","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00125-001-0751-z","article-title":"Self-assembled \u201cnanocubicle\u201d as a carrier for peroral insulin delivery","volume":"45","author":"Chung","year":"2002","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.ecl.2004.11.006_bib178","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1081\/DDC-100107680","article-title":"Enhancement of absorption of insulin-loaded polyisobutylcyanoacrylate nanospheres by sodium cholate after oral and subcutaneous administration in diabetic rats","volume":"27","author":"Radwan","year":"2001","journal-title":"Drug Dev Ind Pharm"},{"issue":"8","key":"10.1016\/j.ecl.2004.11.006_bib179","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.2337\/diacare.23.8.1124","article-title":"Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl-insulin complex in humans","volume":"23","author":"Shojaee-Moradie","year":"2000","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-199733040-00004","article-title":"Pharmacokinetic considerations of new insulin formulations and routes of administration","volume":"33","author":"Hoffman","year":"1997","journal-title":"Clin Pharmacokinet"},{"issue":"17","key":"10.1016\/j.ecl.2004.11.006_bib181","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1056\/NEJM198504253121708","article-title":"Insulin delivery: how, when, and where","volume":"312","author":"Schade","year":"1985","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib182","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2337\/diacare.3.2.270","article-title":"Normal insulin secretion: the goal of artificial insulin delivery systems?","volume":"3","author":"Eaton","year":"1980","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib183","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1210\/jcem-51-3-520","article-title":"Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior","volume":"51","author":"Eaton","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib184","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.metabol.2003.07.021","article-title":"Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: Results from a phase I\/II clinical trial","volume":"53","author":"Clement","year":"2004","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib185","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/152091502760306544","article-title":"Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2","volume":"4","author":"Clement","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.ecl.2004.11.006_bib186","unstructured":"Heise T, Kapitza C, Nosek L, et al. Oral insulin as first line therapy in type 2 diabetes: A randomized-controlled pilot study [late-breaking abstract]. American Diabetes Association, 64th Scientific Sessions, 2004. Orlando, Florida."},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib187","first-page":"A114","article-title":"Pharmacodynamics and pharmcokinetics of dose ranging effects of Oralin s.c. regular insulin in type 1 diabetic subjects","volume":"53","author":"Raz","year":"2004","journal-title":"Diabetes"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2004.11.006_bib188","first-page":"A4","article-title":"Pharmacodymanics and pharmcokinetics of dose ranging effects of Oralin versus S.C. Regular insulin in healthy volunteers","volume":"53","author":"Raz","year":"2004","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib189","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2337\/diacare.26.2.421","article-title":"Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes","volume":"26","author":"Kipnes","year":"2003","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.ecl.2004.11.006_bib190","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1046\/j.1464-5491.2003.01076.x","article-title":"Alternative routes of insulin delivery","volume":"20","author":"Owens","year":"2003","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib191","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2337\/diacare.4.4.454","article-title":"The effectiveness of rectal administration of insulin suppository on normal and diabetic subjects","volume":"4","author":"Yamasaki","year":"1981","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1139\/y81-001","article-title":"The effect of rectal administration of insulin on the short-term treatment of alloxan-diabetic dogs","volume":"59","author":"Yamasaki","year":"1981","journal-title":"Can J Physiol Pharmacol"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib193","first-page":"173","article-title":"Rectal administration of insulin","volume":"20","author":"Raz","year":"1984","journal-title":"Isr J Med Sci"},{"issue":"9","key":"10.1016\/j.ecl.2004.11.006_bib194","first-page":"513","article-title":"Rectal administration of insulin","volume":"6","author":"Ritschel","year":"1984","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0022-3565(25)24258-6","article-title":"Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter","volume":"244","author":"Aungst","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.ecl.2004.11.006_bib196","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.2042-7158.1989.tb06372.x","article-title":"Effectiveness of insulin suppositories in diabetic patients","volume":"41","author":"Nishihata","year":"1989","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib197","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/00003495-199142020-00004","article-title":"Recent developments in insulin delivery techniques. Current status and future potential","volume":"42","author":"Kennedy","year":"1991","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib198","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2337\/diab.35.2.217","article-title":"Control of blood glucose levels in alloxan-diabetic rabbits by iontophoresis of insulin","volume":"35","author":"Kari","year":"1986","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.ecl.2004.11.006_bib199","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00000441-198905000-00009","article-title":"Transdermal delivery of human insulin to albino rabbits using electrical current","volume":"297","author":"Meyer","year":"1989","journal-title":"Am J Med Sci"},{"issue":"9","key":"10.1016\/j.ecl.2004.11.006_bib200","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.2337\/diab.36.9.1068","article-title":"Prolonged release of insulin by cholesterol-matrix implant","volume":"36","author":"Wang","year":"1987","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.ecl.2004.11.006_bib201","doi-asserted-by":"crossref","first-page":"692","DOI":"10.2337\/diab.35.6.692","article-title":"Controlled release of insulin from polymer matrices. Control of diabetes in rats","volume":"35","author":"Brown","year":"1986","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.ecl.2004.11.006_bib202","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2337\/diab.35.6.684","article-title":"Controlled release of insulin from polymer matrices. In vitro kinetics","volume":"35","author":"Brown","year":"1986","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib203","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2337\/diab.29.1.37","article-title":"One month of sustained release of insulin from a polymer implant","volume":"29","author":"Creque","year":"1980","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib204","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/jop.1989.5.81","article-title":"Systemic delivery of insulin through eyes to lower the glucose concentration","volume":"5","author":"Chiou","year":"1989","journal-title":"J Ocul Pharmacol"},{"issue":"6","key":"10.1016\/j.ecl.2004.11.006_bib205","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00262208","article-title":"The life story of the pancreatic B cell","volume":"26","author":"Hellerstrom","year":"1984","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib206","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00006676-199303000-00018","article-title":"In vitro stimulation of hamster pancreatic duct growth by an extract derived from the \u201cwrapped\u201d pancreas","volume":"8","author":"Rosenberg","year":"1993","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib207","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000217834","article-title":"Factors controlling pancreatic islet neogenesis","volume":"14","author":"Vinik","year":"1993","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib208","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00006676-199607000-00005","article-title":"Induction of islet cell differentiation and new islet formation in the hamster\u2013further support for a ductular origin","volume":"13","author":"Rosenberg","year":"1996","journal-title":"Pancreas"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib209","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/BF00418339","article-title":"Islet-cell regeneration in the diabetic hamster pancreas with restoration of normoglycaemia can be induced by a local growth factor(s)","volume":"39","author":"Rosenberg","year":"1996","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib210","first-page":"3","article-title":"Paracrine\/autocrine regulation of pancreatic islet cell proliferation and differentiation in the hamster: studies using parabiosis","volume":"19","author":"Rosenberg","year":"1996","journal-title":"Clin Invest Med"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib211","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-5793(95)01457-8","article-title":"Identification of differentially expressed genes induced in pancreatic islet neogenesis","volume":"378","author":"Rafaeloff","year":"1996","journal-title":"FEBS Lett"},{"issue":"4","key":"10.1016\/j.ecl.2004.11.006_bib212","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1536-4801.1988.tb09581.x","article-title":"The pancreatic duct cell: proliferative capabilities, specific characteristics, metaplasia, isolation, and culture","volume":"7","author":"Githens","year":"1988","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"10.1016\/j.ecl.2004.11.006_bib213","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2337\/diab.37.7.891","article-title":"Morphologic evidence of interactions between adult ductal epithelium of pancreas and fetal foregut mesenchyme","volume":"37","author":"Dudek","year":"1988","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib214","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0022-4804(83)90127-0","article-title":"A new approach to the induction of duct epithelial hyperplasia and nesidioblastosis by cellophane wrapping of the hamster pancreas","volume":"35","author":"Rosenberg","year":"1983","journal-title":"J Surg Res"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib215","first-page":"75","article-title":"Induction of endocrine cell differentiation: a new approach to management of diabetes","volume":"114","author":"Rosenberg","year":"1989","journal-title":"J Lab Clin Med"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib216","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00006676-198902000-00005","article-title":"The effect of cellophane wrapping of the pancreas in the Syrian golden hamster: autoradiographic observations","volume":"4","author":"Rosenberg","year":"1989","journal-title":"Pancreas"},{"issue":"6","key":"10.1016\/j.ecl.2004.11.006_bib217","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1055\/s-2007-979037","article-title":"Induction of pancreatic islet neogenesis","volume":"29","author":"Vinik","year":"1997","journal-title":"Horm Metab Res"},{"issue":"9","key":"10.1016\/j.ecl.2004.11.006_bib218","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1172\/JCI119383","article-title":"Cloning and sequencing of the pancreatic islet neogenesis associated protein (INGAP) gene and its expression in islet neogenesis in hamsters","volume":"99","author":"Rafaeloff","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ecl.2004.11.006_bib219","first-page":"270A","article-title":"Partial purification and characterization of ilotropin, a pancreatic islet specific growth factor","volume":"115","author":"Pittenger","year":"1991","journal-title":"J Cell Biol"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2004.11.006_bib220","first-page":"A256","article-title":"INGAP peptide increases B-cell mass and insulin content in adult hamsters and reverses STZ diabetes","volume":"49","author":"Rosenberg","year":"2000","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2004.11.006_bib221","first-page":"A58","article-title":"Expression, purifcation and characterization of islet neogenesis associated protein (INGAP)","volume":"47","author":"Reifel-Miller","year":"1998","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib222","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1677\/joe.0.1710309","article-title":"Factors mediating the transdifferentiation of islets of Langerhans to duct epithelial-like structures","volume":"171","author":"Wang","year":"2001","journal-title":"J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib223","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2337\/diab.37.3.334","article-title":"Induction of nesidioblastosis will reverse diabetes in Syrian golden hamster","volume":"37","author":"Rosenberg","year":"1988","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.ecl.2004.11.006_bib224","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0022-4804(88)90052-2","article-title":"Preparation of islets of Langerhans from the hamster pancreas","volume":"44","author":"Rosenberg","year":"1988","journal-title":"J Surg Res"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2004.11.006_bib225","first-page":"A256","article-title":"INGAP peptide increases B-cell mass and insulin content in adult hamster and reverses STZ diabetes","volume":"49","author":"Rosenberg","year":"2000","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ecl.2004.11.006_bib226","first-page":"31","article-title":"Quantitative ultrastructural changes induced by sucrose administration in the pancreatic B cells of normal hamsters","volume":"24","author":"Camihort","year":"2000","journal-title":"Biocell"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib227","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/(SICI)1520-7560(199903\/04)15:2<106::AID-DMRR18>3.0.CO;2-2","article-title":"Changes induced by sucrose administration upon the morphology and function of pancreatic islets in the normal hamster","volume":"15","author":"Del Zotto","year":"1999","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib228","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1677\/joe.0.1770243","article-title":"Expression of islet neogenesis-associated protein in islets of normal hamsters","volume":"177","author":"Flores","year":"2003","journal-title":"J Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2004.11.006_bib229","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/joe.0.1770249","article-title":"Pancreatic duodenal homeobox-1 and islet neogenesis-associated protein: a possible combined marker of activateable pancreatic cell precursors","volume":"177","author":"Gagliardino","year":"2003","journal-title":"J Endocrinol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852904001033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852904001033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:21:21Z","timestamp":1760174481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852904001033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":229,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0889852904001033"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2004.11.006","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Pharmacologic Agents for Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2004.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}